PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE
n n n
n NURSE PRESCRIBERS 6TH EDITION WOO ROBINSON TEST
n n n n n n
nBANK
, PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE n n n
nCAREGIVER PRESCRIBERS 6TH EDITION WOO ROBINSON TEST
n n n n n n
BANK n
CH n n1. nThe nRole nof nthe nCaregiver
PractitionernMultiple nselection
n
Identify nthe noption nthat nbest ncompletes nthe nstatement nor nanswers nthe nquestion.
n 1. nNurse npractitioner nprescriptive nauthority nis nregulated nby:
1. The nNational nCouncil nof nState nBoards nof nNursing
2. The nU.S. nMedical ndrug nEnforcement nAdministration
3. The nState nBoard nof nNursing nfor neach nstate
4. The nState nBoard nof nPharmacy
n 2. nThe nbenefits nto nthe nhospital nclient nof nhaving nan nAdvanced nPractice nRegistered
nCaregiver n(APRN) nprescribern include:
1. Caregivers nknow nmore nabout nPharmacology nthan nother nprescribers
nbecause nthey ntake nitnboth nin ntheir nbasic nnursing nprogram nand nin ntheir
nAPRN nprogram.
2. Caregivers ncare nfor nthe nhospital nclient nfrom na nholistic napproach
nand ninclude nthe nhospital nclient ninn decision nmaking nregarding ntheir
ncare.
3. APRNs nare nless nlikely nto nprescribe nnarcotics nand nother ncontrolled nsubstances.
4. APRNs nare nable nto nprescribe nindependently nin nall nstates, nwhereas na
nphysician’sn assistant nneeds nto nhave na nphysician nsupervising ntheir
npractice.
n 3. nClinical njudgment nin nprescribing nincludes:
1. Factoring nin nthe ncost nto nthe nhospital nclient nof nthe nmedication nprescribed
2. Always nprescribing nthe nnewest nmedication navailable nfor nthe ndisease nprocess
3. Handing nout nmedical ndrug nsamples nto npoor nhospital nclients
4. Prescribing nall ngeneric nmedications nto ncut ncosts
n 4. nCriteria nfor nchoosing nan neffective nmedical ndrug nfor na ndisorder ninclude:
1. Asking nthe nhospital nclient nwhat nmedical ndrug nthey nthink nwould nwork nbest nfor nthem
2. Consulting nnationally nrecognized nguidelines nfor ndisease nmanagement
3. Prescribing nmedications nthat nare navailable nas nsamples nbefore nwriting na nprescription
4. Following nU.S. nDrug nEnforcement nAdministration nguidelines nfor nprescribing
n 5. nCaregiver npractitioner npractice nmay nthrive nunder nhealth-care nreform nbecause nof:
1. The ndemonstrated nability nof ncaregiver npractitioners nto ncontrol ncosts nand
nimprove nhospital nclient noutcomes
2. The nfact nthat ncaregiver npractitioners nwill nbe nable nto npractice nindependently
3. The nfact nthat ncaregiver npractitioners nwill nhave nfull nreimbursement
nunder nhealth-caren reform
4. The nability nto nshift naccountability nfor nMedicaid nto nthe nstate nlevel
,CH n n1. nThe nRole nof nthe nCaregiver
nPractitionernAnswer nSection
MULTIPLE nSELECTION
1. 3 PTS: 1
nACCU
RATE
nANSW
ER:
2. 2 PTS: 1
nACCU
RATE
nANSW
ER:
3. 1 PTS: 1
nACCU
RATE
nANSW
ER:
4. 2 PTS: 1
nACCU
RATE
nANSW
ER:
5. 1 PTS: 1
nACCU
RATE
nANSW
ER:
CH n n2. nReview nof nBasic nPrinciples nof nPharmacology
Multiple nselection
Identify nthe noption nthat nbest ncompletes nthe nstatement nor nanswers nthe nquestion.
n 1. nA nhospital nclient’s nnutritional nintake nand nlaboratory nresults nreflect
nhypoalbuminemia. nThis nis ncritical nton prescribing nbecause:
1. Distribution nof nmedical ndrugs nto ntarget ntissue nmay nbe naffected.
2. The nsolubility nof nthe nmedical ndrug nwill nnot nmatch nthe nsite nof nabsorption.
3. There nwill nbe nless nfree nmedical ndrug navailable nto ngenerate nan neffect.
4. Medical ndrugs nbound nto nalbumin nare nreadily nexcreted nby nthe nkidneys.
n 2. nMedical ndrugs nthat nhave na nsignificant nfirst-pass neffect:
1. Must nbe ngiven nby nthe nenteral n(oral) nroute nonly
2. Bypass nthe nhepatic ncirculation
3. Are nrapidly nmetabolized nby nthe nliver nand nmay nhave nlittle nif nany ndesired naction
4. Are nconverted nby nthe nliver nto nmore nactive nand nfat-soluble nforms
n 3. nThe nroute nof nexcretion nof na nvolatile nmedical ndrug nwill nlikely nbe nthe:
1. Kidneys
, 2. Lungs
3. Bile nand nfeces
4. Skin
n 4. nMedroxyprogesterone n(Depo nProvera) nis nprescribed nintramuscularly n(IM) nto
ncreate na nstoragen
reservoir nof nthe nmedical ndrug. nStorage nreservoirs:
1. Assure nthat nthe nmedical ndrug nwill nreach nits nintended ntarget ntissue
2. Are nthe nreason nfor ngiving nloading ndoses
3. Increase nthe nlength nof ntime na nmedical ndrug nis navailable nand nactive
4. Are nmost ncommon nin ncollagen ntissues
n 5. nThe nNP nchooses nto ngive ncephalexin nevery n8 nhours nbased non nknowledge nof nthe nmedical
drug’s:
n
1. Propensity nto ngo nto nthe ntarget nreceptor
2. Biological nhalf-life
3. Pharmacodynamics
4. Safety nand nside neffects
6. nAzithromycin ndosing nrequires nthat nthe nfirst nday’s ndosage nbe ntwice nthose nof nthe
nother n4 ndays nof nthen
prescription. nThis nis nconsidered na nloading ndose. nA nloading
ndose:
1. Rapidly nachieves nmedical ndrug nlevels nin nthe ntherapeutic nrange
2. Requires nfour- nto nfive-half-lives nto nattain
3. Is ninfluenced nby nrenal nfunction
4. Is ndirectly nrelated nto nthe nmedical ndrug ncirculating nto nthe ntarget ntissues
n 7. nThe npoint nin ntime non nthe nmedical ndrug nconcentration ncurve nthat nindicates nthe nfirst
nsign nof na ntherapeutic neffectn
is nthe:
1. Minimum nadverse neffect nlevel
2. Peak nof naction
3. Onset nof naction
4. Therapeutic nrange
n 8. nPhenytoin nrequires nthat na ntrough nlevel nbe ndrawn. nPeak nand ntrough nlevels nare ndone:
1. When nthe nmedical ndrug nhas na nwide ntherapeutic nrange
2. When nthe nmedical ndrug nwill nbe nadministered nfor na nshort ntime nonly
3. When nthere nis na nhigh ncorrelation nbetween nthe ndose nand nsaturation nof nreceptor nsites
4. To ndetermine nif na nmedical ndrug nis nin nthe ntherapeutic nrange
n 9. nA nlaboratory nresult nindicates nthat nthe npeak nlevel nfor na nmedical ndrug nis nabove nthe
nminimum ntoxic nconcentration.
This nmeans nthat nthe:
1. Concentration nwill nproduce ntherapeutic neffects
2. Concentration nwill nproduce nan nadverse nresponse
3. Time nbetween ndoses nmust nbe nshortened
4. Duration nof naction nof nthe nmedical ndrug nis ntoo nlong
n n n 10. nMedical ndrugs nthat nare nreceptor nagonists nmay ndemonstrate nwhat nproperty?
1. Irreversible nbinding nto nthe nmedical ndrug nreceptor nsite
2. Upregulation nwith nchronic nuse
3. Desensitization nor ndownregulation nwith ncontinuous nuse
4. Inverse nrelationship nbetween nmedical ndrug nconcentration nand nmedical ndrug naction
n n n
n NURSE PRESCRIBERS 6TH EDITION WOO ROBINSON TEST
n n n n n n
nBANK
, PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE n n n
nCAREGIVER PRESCRIBERS 6TH EDITION WOO ROBINSON TEST
n n n n n n
BANK n
CH n n1. nThe nRole nof nthe nCaregiver
PractitionernMultiple nselection
n
Identify nthe noption nthat nbest ncompletes nthe nstatement nor nanswers nthe nquestion.
n 1. nNurse npractitioner nprescriptive nauthority nis nregulated nby:
1. The nNational nCouncil nof nState nBoards nof nNursing
2. The nU.S. nMedical ndrug nEnforcement nAdministration
3. The nState nBoard nof nNursing nfor neach nstate
4. The nState nBoard nof nPharmacy
n 2. nThe nbenefits nto nthe nhospital nclient nof nhaving nan nAdvanced nPractice nRegistered
nCaregiver n(APRN) nprescribern include:
1. Caregivers nknow nmore nabout nPharmacology nthan nother nprescribers
nbecause nthey ntake nitnboth nin ntheir nbasic nnursing nprogram nand nin ntheir
nAPRN nprogram.
2. Caregivers ncare nfor nthe nhospital nclient nfrom na nholistic napproach
nand ninclude nthe nhospital nclient ninn decision nmaking nregarding ntheir
ncare.
3. APRNs nare nless nlikely nto nprescribe nnarcotics nand nother ncontrolled nsubstances.
4. APRNs nare nable nto nprescribe nindependently nin nall nstates, nwhereas na
nphysician’sn assistant nneeds nto nhave na nphysician nsupervising ntheir
npractice.
n 3. nClinical njudgment nin nprescribing nincludes:
1. Factoring nin nthe ncost nto nthe nhospital nclient nof nthe nmedication nprescribed
2. Always nprescribing nthe nnewest nmedication navailable nfor nthe ndisease nprocess
3. Handing nout nmedical ndrug nsamples nto npoor nhospital nclients
4. Prescribing nall ngeneric nmedications nto ncut ncosts
n 4. nCriteria nfor nchoosing nan neffective nmedical ndrug nfor na ndisorder ninclude:
1. Asking nthe nhospital nclient nwhat nmedical ndrug nthey nthink nwould nwork nbest nfor nthem
2. Consulting nnationally nrecognized nguidelines nfor ndisease nmanagement
3. Prescribing nmedications nthat nare navailable nas nsamples nbefore nwriting na nprescription
4. Following nU.S. nDrug nEnforcement nAdministration nguidelines nfor nprescribing
n 5. nCaregiver npractitioner npractice nmay nthrive nunder nhealth-care nreform nbecause nof:
1. The ndemonstrated nability nof ncaregiver npractitioners nto ncontrol ncosts nand
nimprove nhospital nclient noutcomes
2. The nfact nthat ncaregiver npractitioners nwill nbe nable nto npractice nindependently
3. The nfact nthat ncaregiver npractitioners nwill nhave nfull nreimbursement
nunder nhealth-caren reform
4. The nability nto nshift naccountability nfor nMedicaid nto nthe nstate nlevel
,CH n n1. nThe nRole nof nthe nCaregiver
nPractitionernAnswer nSection
MULTIPLE nSELECTION
1. 3 PTS: 1
nACCU
RATE
nANSW
ER:
2. 2 PTS: 1
nACCU
RATE
nANSW
ER:
3. 1 PTS: 1
nACCU
RATE
nANSW
ER:
4. 2 PTS: 1
nACCU
RATE
nANSW
ER:
5. 1 PTS: 1
nACCU
RATE
nANSW
ER:
CH n n2. nReview nof nBasic nPrinciples nof nPharmacology
Multiple nselection
Identify nthe noption nthat nbest ncompletes nthe nstatement nor nanswers nthe nquestion.
n 1. nA nhospital nclient’s nnutritional nintake nand nlaboratory nresults nreflect
nhypoalbuminemia. nThis nis ncritical nton prescribing nbecause:
1. Distribution nof nmedical ndrugs nto ntarget ntissue nmay nbe naffected.
2. The nsolubility nof nthe nmedical ndrug nwill nnot nmatch nthe nsite nof nabsorption.
3. There nwill nbe nless nfree nmedical ndrug navailable nto ngenerate nan neffect.
4. Medical ndrugs nbound nto nalbumin nare nreadily nexcreted nby nthe nkidneys.
n 2. nMedical ndrugs nthat nhave na nsignificant nfirst-pass neffect:
1. Must nbe ngiven nby nthe nenteral n(oral) nroute nonly
2. Bypass nthe nhepatic ncirculation
3. Are nrapidly nmetabolized nby nthe nliver nand nmay nhave nlittle nif nany ndesired naction
4. Are nconverted nby nthe nliver nto nmore nactive nand nfat-soluble nforms
n 3. nThe nroute nof nexcretion nof na nvolatile nmedical ndrug nwill nlikely nbe nthe:
1. Kidneys
, 2. Lungs
3. Bile nand nfeces
4. Skin
n 4. nMedroxyprogesterone n(Depo nProvera) nis nprescribed nintramuscularly n(IM) nto
ncreate na nstoragen
reservoir nof nthe nmedical ndrug. nStorage nreservoirs:
1. Assure nthat nthe nmedical ndrug nwill nreach nits nintended ntarget ntissue
2. Are nthe nreason nfor ngiving nloading ndoses
3. Increase nthe nlength nof ntime na nmedical ndrug nis navailable nand nactive
4. Are nmost ncommon nin ncollagen ntissues
n 5. nThe nNP nchooses nto ngive ncephalexin nevery n8 nhours nbased non nknowledge nof nthe nmedical
drug’s:
n
1. Propensity nto ngo nto nthe ntarget nreceptor
2. Biological nhalf-life
3. Pharmacodynamics
4. Safety nand nside neffects
6. nAzithromycin ndosing nrequires nthat nthe nfirst nday’s ndosage nbe ntwice nthose nof nthe
nother n4 ndays nof nthen
prescription. nThis nis nconsidered na nloading ndose. nA nloading
ndose:
1. Rapidly nachieves nmedical ndrug nlevels nin nthe ntherapeutic nrange
2. Requires nfour- nto nfive-half-lives nto nattain
3. Is ninfluenced nby nrenal nfunction
4. Is ndirectly nrelated nto nthe nmedical ndrug ncirculating nto nthe ntarget ntissues
n 7. nThe npoint nin ntime non nthe nmedical ndrug nconcentration ncurve nthat nindicates nthe nfirst
nsign nof na ntherapeutic neffectn
is nthe:
1. Minimum nadverse neffect nlevel
2. Peak nof naction
3. Onset nof naction
4. Therapeutic nrange
n 8. nPhenytoin nrequires nthat na ntrough nlevel nbe ndrawn. nPeak nand ntrough nlevels nare ndone:
1. When nthe nmedical ndrug nhas na nwide ntherapeutic nrange
2. When nthe nmedical ndrug nwill nbe nadministered nfor na nshort ntime nonly
3. When nthere nis na nhigh ncorrelation nbetween nthe ndose nand nsaturation nof nreceptor nsites
4. To ndetermine nif na nmedical ndrug nis nin nthe ntherapeutic nrange
n 9. nA nlaboratory nresult nindicates nthat nthe npeak nlevel nfor na nmedical ndrug nis nabove nthe
nminimum ntoxic nconcentration.
This nmeans nthat nthe:
1. Concentration nwill nproduce ntherapeutic neffects
2. Concentration nwill nproduce nan nadverse nresponse
3. Time nbetween ndoses nmust nbe nshortened
4. Duration nof naction nof nthe nmedical ndrug nis ntoo nlong
n n n 10. nMedical ndrugs nthat nare nreceptor nagonists nmay ndemonstrate nwhat nproperty?
1. Irreversible nbinding nto nthe nmedical ndrug nreceptor nsite
2. Upregulation nwith nchronic nuse
3. Desensitization nor ndownregulation nwith ncontinuous nuse
4. Inverse nrelationship nbetween nmedical ndrug nconcentration nand nmedical ndrug naction
